Toronto, ON; December 12, 2024 – Proteocyte Diagnostics announces its partnership with Pharmackt (www.pharmackt.com) to introduce their Oral Cancer Stratification Test, Straticyte, in Turkey for the first time. Pharmackt represents numerous pioneering Molecular Diagnostic companies in the field of Oncology. The World Health Organization’s Global Cancer Observatory data indicates that the prevalence of oral cancer within the population of Turkey is relatively high, with significant numbers of new cases and deaths reported annually. The tongue is the most affected area within the oral cavity; however, comprehensive research on oral cancer in Turkey remains limited.
Oral cancer often necessitates major surgery, can severely impact a patient’s quality of life, and may even lead to death. Early detection and prognosis is critical as late-stage oral cancers are very difficult and costly to treat. Straticyte™ examines biomarkers related to oral lesions. Since every lesion is unique, understanding its biology provides additional information for both patients and doctors, enabling more confident and informed decisions about care.
“This is an exciting initiative towards our global expansion” states Mark Hammar, CEO of Proteocyte. “Turkey is the first step to expand outside of North America and we will continue to seek new markets that can benefit from the innovative Straticyte test.”
– 30 –
About Proteocyte
Proteocyte, Inc. is a personalized medicine and diagnostics company located in MaRS Center,
Toronto ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. Straticyte™, the company’s oral dysplasia predictive test, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.
For more information please contact:
Todd Conrad
Sales & Marketing Advisor
416-779-4806
[email protected]